Updates are available Correction dated 2023-06-19
Click to view Correction: https://doi.org/10.1186/s10194-023-01606-0
-
Authors
Guo, Song
Ernstsen, Charlotte
Hay-Schmidt, Anders
Kristensen, David Møbjerg
Ashina, Messoud
Olesen, Jes
Christensen, Sarah Louise
-
Funding
Funding for this research was provided by:
BRIDGE – Translational Excellence Programme at the Faculty of Health and Medical Sciences, University of Copenhagen (NNF20SA0064340)
Candys Foundation
Lundbeck Foundation Professor Grant (R310-2018–3711)
- License Information
-
More Information
Article History
Received: 2 August 2022
Accepted: 4 November 2022
First Online: 5 December 2022
Change Date: 19 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s10194-023-01606-0
Declarations
:
: The experiments were conducted in accordance with ARRIVE guidelines and approved by the Danish Animal Experiments Inspectorate (ethical approval number 2017–15-0201–01,358).
: Jes Olesen owns the start-up company Cephagenics. MA is a consultant, speaker, or scientific advisor for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva; primary investigator for AbbVie, Amgen and Lundbeck ongoing trials. MA has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associate editor of <i>Cephalalgia</i>, associate editor of the <i>Journal of Headache and Pain</i>, and associate editor of <i>Brain</i>. All other authors report no competing interests.
